Добірка наукової літератури з теми "Muhammad (12..-1360)"

Background Acute kidney injury (AKI) is a common problemin hospitalized pediatric patients, with effects on morbidity andmortality.Objectives To assess for the incidence and common etiologies ofAKI, as well as to review factors that affect patient outcomes atMuhammad Husin Hospital, Palembang.Methods We reviewed data from our nephrology registry fromJanuary 2010 to June 2013. Independent variables were age, stageand etiology of AKI, requirement of renal replacement therapy(RRT) , and PICU admission. The dependent variable was patientoutcomes, categorized as survived or died. Association betweenclinical data and outcomes were analyzed by Chi-square test.Results The incidence of AKI was 28.3%. Using the pediatric risk,injury, failure, loss, end stage renal disease (pRIFLE) criteria, 65(36.7%) patients were in the risk stage, 56 (31.6%) in the injurystage, and 56 (31.6%) in the failure stage. Twelve (6.8%) patientsrequired RRT and 29 (16.4%) patients were admitted to the PIW.The mortality rate from AKI was 20.9%. The common etiologies ofAKI were acute glomerulonephritis (55 subjects; 31.1 % ), multipleorgan dysfunction (24 subjects; 13.6%), dehydration (23 subjects;13.0%), hypoalbuminemia (20 subjects; 11.3%), heart failure (11subjects; 6.2%) and nephrotoxic agents (12 subjects; 6.8%) . Themortality rate was significantly higher in children of younger age(<5 years) (P=0.0001), in the failure stage of AKI (P=0.014),with non-renal origin of illness (P=0.0001) and those with anindication for PIW admission (P=0.0001).Conclusion AKI is found in one-third of nephrology patients.The most common etiology of AKI is acute glomerulonephritis.One-fifth of patients with AKI do not survive. Recognition ofriskfactors and detection of AKI in early stages might improve patientoutcomes.

Background:Chronic and steady asymptomatic hyperuricemia (AHU) can eventually lead to the deposition of monosodium urate crystals in joints and soft tissues. The rate of progression from AHU to clinically evident gout varies and mainly depends on serum uric acid levels. However, little is known about the prognostic value of ultrasonographic findings in individuals with AHU in detail.Objectives:To explore the prognostic value of ultrasonographic findings in individuals with asymptomatic hyperuricemia.Methods:We analyzed the ultrasonographic findings (snowstorm sign, double-contour (DC) sign, tophi, bone erosion, and abnormal blood flow) of bilateral knees, ankles and the first metatarsal-phalangeal joints (1st MTP) of individuals with AHU at Peking University People’s hospital between June 2014 and May 2016. All individuals were followed up for two years.Results:Among 218 individuals with AHU, the prevalence of snowstorm sign, DC sign, tophi, bone erosion and abnormal blood flow was 41%, 23%, 4%, 9% and 13%, respectively. Gout attacked in 36 patients during 2-year follow-up with 4.5 years of HU duration. The first attack affected the 1st MTP in 60%, the ankle in 31%, and the knee in 11% of the patients with gout. Patients with gout attack has longer hyperuricemia duration compared with individuals with AHU without gout attack. DC sign, tophi, and bone erosion on ultrasound were more frequently presented in patients with gout attack compared with individuals with AHU without gout attack. However, the prevalence of snowstorm sign and and abnormal blood flow on ultrasound has no significant differences between patients with gout attack and individuals with AHU without gout attack.Conclusion:Longer hyperuricemia duration, DC sign, tophi, and bone erosion on ultrasound in individuals with AHU could be associated with gout attack.References:[1]Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-98.[2]Estevez-Garcia IO, Gallegos-Nava S, Vera-Pérez E, Silveira LH, Ventura-Ríos L, Vancini G, et al. Levels of cytokines and MicroRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: A Bench-to-Bedside Approach. Arthritis Care Res. 2018;70(12):1814-21.[3]Elsaman AM, Muhammad EM, Pessler F. Sonographic findings in gouty arthritis: diagnostic value and association with disease duration. Ultrasound Med Biol. 2016;42(6):1330-6.[4]Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75-86.Acknowledgments:This work was supported by National Natural Science Foundation of China (No. 81571684 to Jiaan Zhu), Peking University People’s Hospital Research and Development Funds (RDC2014-02 to Wenting Fan).Disclosure of Interests:None declared

The aim of the study was to evaluated the effect of giving water hyacinth and fish oil in quail diet on the performance, egg cholesterol and egg fatty acid profile. This study used 200 unsex day old quail divided into 5 treatments and 4 replications that were reared 5 weeks and then selected male or female. The results of sexing quail at week 5 were 95 females and 86 males. Growth period diets (0-5 weeks) contains 24% crude protein and metabolic energy of 2900 kcal kg-1 and production period diets (5-12 weeks) contains 22% crude protein and 2900 kcal kg-1. The experimental design used a completely randomized design with the treatment of using water hyacinth that was 0%,1%, 2%, 3 % and 4% with fish oil which was 0%, 4%, 5%, 6% and 7% in quail diet. The variables measured were quail performance (0-5 week age and 5-12 week age), egg cholesterol, and egg fatty acid profile. The results showed that using of water hyacinth meal 1% -4% and fish oil 4%-5% in the diet of the growth period resulted in higher feed consumption and body weight gain than diet without water hyacinth and fish oil but feed conversion rasio were same. Quail performance of the production period was not affected by all treatments. Unsaturated fatty acids tend to increased in quail eggs. The lowest cholesterol level of quail eggs was by giving 2% of water hyacinth meal and 5% of fish oil in the diet. It was concluded that water hyacinth can be used as local feed ingredients in quail diet until 4%. Key words: Coturnix coturnix japonica, egg cholesterol, egg fatty acid profile, performance, production DAFTAR PUSTAKA Aboul-Enein AM, Al-Abd A, Shalaby EA, Abul-Ela F, Nasr-Allah AA & Mahmoud AM. 2011. Eichornia crassipes (MarT) solm. Plant Signal Behaviour. 6(6): 834-836 Afrose S, Hossain MS & Tsuji H. 2010. Effect of dietary karaya saponin on serum and egg yolk cholesterol in laying hens. British Poultry Science. 51 (6) : 797-804 Adeyemi OA, Adekoya JA & Abayomi R. 2012. Performance of broiler chickens fed diets containing cassave leaf: blood meal mix as replacement for soybean meal. Revista Cientifica UDO Agricola. 12 (1): 212-219 Aziz Z, Cyriac S, Beena V & Philomina PT. 2012.Comparison of cholesterol content in chicken, duck and quail eggs. Journal Veterinary Animal Science. 43: 64-66 Bragagnolo N & Rodriguez-Amaya DB. 2003. Comparison of the cholesterol content of Brazilian chicken and quail eggs. Journal of food Composition and Analysis. 16(2): 147-153 Chimote MJ, Barmase BS, Raut AS, Dhok AP & Kuralkar SV.2009. Effect of supplementation of probiotic and enzymes on performance of Japanese quails. Veterinary World. 2 (6): 219-220 Damongilala LJ. 2008. Kandungan asam lemak tak jenuh minyak hati ikan cucut botol (Cenctrophorus sp) yang diekstraksi dengan cara pemanasan. Jurnal Ilmiah Sains. 8(2): 249-253 Grigorova S, Nikolova M, Penkov D & Gerzilov V. 2014. Egg yolk lipid change in Japanese given Tribulus terrestris extract. Bulgarian Journal of Agricultural Science. 20 (6) : 1472-1476 Guclu BK, Uyanik F & Iscan KM. 2008. Effect of dietary oil sources on egg quality, fatty acid composition of eggs and blood lipids in laying quail. South American Journal of Animal Science. 38 (2): 91-100 Hartoyo B, Irawan I & Iriyanti N. 2005. Pengaruh asam lemak dan kadar serat kasar yang berbeda dalam ransum broiler terhadap kandungan kolesterol, HDL dan LDL serum darah. Animal Production. 7(1):27-33. Hemid, AEA, El-Gawad AAH, El-Wardany I, El-Daly EF & El-Azeem NAA. 2010. Alleviating effect of some environmental stress factors on productive performance in Japanese quail 2.Laying performance. World Journal of Agricultural Science. 6(5): 517-524 Hilmi M, Sumiati & Astuti DA.2015. Egg production and physical quality in Coturnix coturnix japonica fed diet containing piperine as phytogenic feed additive. Media Peternakan. 38(3): 150-155 Kamely M, Torshizi MAK & Khosravinia H. 2016. Omega 3 enrichment of quail eggs: age, fish oil, and savory essensial oil. Journal of Agricultural Science and Technology. 18 (2): 347-359 Khairani, Sumiati & Wiryawan KG. 2016. Egg production and quality of quails fed diets with varying levels of methionine and choline chloride. Media Peternakan. 39 (1): 34-39 Kurniawan M, Izzati M & Nurchayati Y. 2010. Kandungan klorofil, karotenoid, dan vitamin C pada beberapa spesies tumbuhan akuatik. Buletin Anatomi dan Fisiologi. 18(1):28-40 Leeson S & Summers JD. 2005. Commercial Poultry Nutrition. Third Edition. Canada (CA): Nottingham University Pr. LiYX, Wang YQ, Pang YZ, Li JX, Xie XH, Guo TJ & Li WQ. 2011. The effect of crude protein level in diets on laying performance, nutrien digestibility of yellow quails. International Journal of Poultry Science. 10(2): 110-112 Malik AA, Aremu A, Ayanwale BA & Ijaiya. AT 2016. A Nutritional evaluation of water hyacinth (Eichhornia crassipes. Martius Solms-laubach) meal diets supplemented with Maxigrain* Enzyme for growing pulllets. Journal of Raw Material Research Nigeria. 10(2): 18-44 Mahmood M, Sial AR, Saima, Akram M, Pasha TN & Jabbar MA. 2014. Effect of dietary energy levels on growth performance and feed cost analysis in Japanese quail. Pakistan Journal of Zoology. 45(5): 1357-1362 Mangisah I, Tristiarti, Murningsih W, Nasoetion MH, Jayanti ES & Astuti Y. 2006. Kecernaan nutrien eceng gondok yang difermentasi dengan Aspergillus niger pada ayam broiler. Journal of Indonesian Tropical Animal Agricultural. 31 (2): 124-128 Maulana IT, Sukraso & Damayanti S. 2014 .Kandungan asam lemak dalam minyak ikan Indonesia. Jurnal Ilmu dan Teknologi Kelautan Tropis. 6(1): 121-130 Metwally AA, El-Gellal AM & El-Sawaisi SM. 2009). Effect of silymarin on lipid metabolism in rat. World Applied Sciences Journal. 6 (12): 1634-1637 Mona MH, Morsy AS & Hasan AM. 2013. Egg yolk cholesterol and productive performance of laying hens influenced by dietary crude fiber levels under drinking natural salin water. Journal of Animal and Poultry Production. 4(3): 161-176 Muhammad M, Peter S, James G & Wosilat A. 2015. Growth performance of growing quails (Coturnix japonica) fed graded levels of Neem. International Journal of Applied Research. 1(2): 04-07 NRC.1994. Nutrient Requirement of Poultry. 9th Edition. Wahington D.C (US): National Academy Odo BI & Nnadi AE. 2014. Growth response of quails (Coturnix coturnix japonica) to varying levels of cassava (Manihot esculenta) tuber meal as a replacement for maize (Zea mays). American Journal of Experimental Agricultural. 4(12): 1898-1903 Riswandi. 2014. Kualitas silase eceng gondok (Eichhornia crassipes) dengan penambahan dedak halus dan ubi kayu. Jurnal Peternakan Sriwijaya. 3(1): 1-6 Rusmana,D. 2007. Pengaruh substitusi minyak sawit oleh minyak ikan lemuru dan suplementasi vitamin E dalam ransum ayam broiler terhadap performans. Jurnal Ilmu Ternak. 7(2): 101-106 Saha S. & Ray AK. 2011. Evaluation of nutritive value of water hyacinth (Eichhornia crassipes) leaf meal in compound diets for rohu Labeo rohita (Hamilton, 1822) fingerlings after fermentation with two bacterial strains isolated from fish gut. Turkish Journal of Fisheries and Aquatic Science. 11: 199-207 Sastrodihardjo S, Suci DM & Cahyanto MN. 1998. Penggunaan Minyak Ikan Lemuru dan Minyak Kelapa Sawit dalam ransum terhadap Kandungan Asam lemak Omega 3 dan Omega 6 dalam Kuning Telur Ayam. Bogor (ID): Seminar Nasional Peternakan dan Veteriner. Penelitian dan Pengembangan Pertanian Savory CJ & Gentle MJ. 1976. Changes in food intake and gut size in Japanese quail in response to manipulation of dietary fibre content. British Poultry Science. 17(6): 571-580 Sotolu AO & Sule SO. 2011. Digestibility and performance of water hyacinth meal in the diets of African catfish (Clarias gariepinus BURCHELL, 1822). Tropical and Subtropical Agroecosystem. 14: 245-250 Sim JS, Kitts WD & Bragg DB. 1984. Effect of dietary saponin on egg cholesterol level and laying hen performance. Canadian Journal of Animal Science. 64: 97-98 Tyagi T & Agarwal M. 2017. Antioxidant properties and phenolic compound in methanolic extracts of Eichornia crassipes. Reserarch journal of Phytochemistry. 11(2): 85-89. Tolik D, Polawska E, Charuta A, Nowaczewski S & Cooper R. 2014.Characteristics of egg parts, chemical composition and nutritive value of Japanese quail eggs-a review. Folia Biological (Krakow). 62 (4): 287-292 Tunsaringkarn T, Tungjaroenchai W & Siriwong W. 2013. Nutrient benefits of quail (Coturnix coturnix japonica) eggs. International Journal of Scientific and Research Publications. 3(5): 1-8

The aim of the study was to evaluated the effect of giving water hyacinth and fish oil in quail diet on the performance, egg cholesterol and egg fatty acid profile. This study used 200 unsex day old quail divided into 5 treatments and 4 replications that were reared 5 weeks and then selected male or female. The results of sexing quail at week 5 were 95 females and 86 males. Growth period diets (0-5 weeks) contains 24% crude protein and metabolic energy of 2900 kcal kg-1 and production period diets (5-12 weeks) contains 22% crude protein and 2900 kcal kg-1. The experimental design used a completely randomized design with the treatment of using water hyacinth that was 0%,1%, 2%, 3 % and 4% with fish oil which was 0%, 4%, 5%, 6% and 7% in quail diet. The variables measured were quail performance (0-5 week age and 5-12 week age), egg cholesterol, and egg fatty acid profile. The results showed that using of water hyacinth meal 1% -4% and fish oil 4%-5% in the diet of the growth period resulted in higher feed consumption and body weight gain than diet without water hyacinth and fish oil but feed conversion rasio were same. Quail performance of the production period was not affected by all treatments. Unsaturated fatty acids tend to increased in quail eggs. The lowest cholesterol level of quail eggs was by giving 2% of water hyacinth meal and 5% of fish oil in the diet. It was concluded that water hyacinth can be used as local feed ingredients in quail diet until 4%. Key words: Coturnix coturnix japonica, egg cholesterol, egg fatty acid profile, performance, production DAFTAR PUSTAKA Aboul-Enein AM, Al-Abd A, Shalaby EA, Abul-Ela F, Nasr-Allah AA & Mahmoud AM. 2011. Eichornia crassipes (MarT) solm. Plant Signal Behaviour. 6(6): 834-836 Afrose S, Hossain MS & Tsuji H. 2010. Effect of dietary karaya saponin on serum and egg yolk cholesterol in laying hens. British Poultry Science. 51 (6) : 797-804 Adeyemi OA, Adekoya JA & Abayomi R. 2012. Performance of broiler chickens fed diets containing cassave leaf: blood meal mix as replacement for soybean meal. Revista Cientifica UDO Agricola. 12 (1): 212-219 Aziz Z, Cyriac S, Beena V & Philomina PT. 2012.Comparison of cholesterol content in chicken, duck and quail eggs. Journal Veterinary Animal Science. 43: 64-66 Bragagnolo N & Rodriguez-Amaya DB. 2003. Comparison of the cholesterol content of Brazilian chicken and quail eggs. Journal of food Composition and Analysis. 16(2): 147-153 Chimote MJ, Barmase BS, Raut AS, Dhok AP & Kuralkar SV.2009. Effect of supplementation of probiotic and enzymes on performance of Japanese quails. Veterinary World. 2 (6): 219-220 Damongilala LJ. 2008. Kandungan asam lemak tak jenuh minyak hati ikan cucut botol (Cenctrophorus sp) yang diekstraksi dengan cara pemanasan. Jurnal Ilmiah Sains. 8(2): 249-253 Grigorova S, Nikolova M, Penkov D & Gerzilov V. 2014. Egg yolk lipid change in Japanese given Tribulus terrestris extract. Bulgarian Journal of Agricultural Science. 20 (6) : 1472-1476 Guclu BK, Uyanik F & Iscan KM. 2008. Effect of dietary oil sources on egg quality, fatty acid composition of eggs and blood lipids in laying quail. South American Journal of Animal Science. 38 (2): 91-100 Hartoyo B, Irawan I & Iriyanti N. 2005. Pengaruh asam lemak dan kadar serat kasar yang berbeda dalam ransum broiler terhadap kandungan kolesterol, HDL dan LDL serum darah. Animal Production. 7(1):27-33. Hemid, AEA, El-Gawad AAH, El-Wardany I, El-Daly EF & El-Azeem NAA. 2010. Alleviating effect of some environmental stress factors on productive performance in Japanese quail 2.Laying performance. World Journal of Agricultural Science. 6(5): 517-524 Hilmi M, Sumiati & Astuti DA.2015. Egg production and physical quality in Coturnix coturnix japonica fed diet containing piperine as phytogenic feed additive. Media Peternakan. 38(3): 150-155 Kamely M, Torshizi MAK & Khosravinia H. 2016. Omega 3 enrichment of quail eggs: age, fish oil, and savory essensial oil. Journal of Agricultural Science and Technology. 18 (2): 347-359 Khairani, Sumiati & Wiryawan KG. 2016. Egg production and quality of quails fed diets with varying levels of methionine and choline chloride. Media Peternakan. 39 (1): 34-39 Kurniawan M, Izzati M & Nurchayati Y. 2010. Kandungan klorofil, karotenoid, dan vitamin C pada beberapa spesies tumbuhan akuatik. Buletin Anatomi dan Fisiologi. 18(1):28-40 Leeson S & Summers JD. 2005. Commercial Poultry Nutrition. Third Edition. Canada (CA): Nottingham University Pr. LiYX, Wang YQ, Pang YZ, Li JX, Xie XH, Guo TJ & Li WQ. 2011. The effect of crude protein level in diets on laying performance, nutrien digestibility of yellow quails. International Journal of Poultry Science. 10(2): 110-112 Malik AA, Aremu A, Ayanwale BA & Ijaiya. AT 2016. A Nutritional evaluation of water hyacinth (Eichhornia crassipes. Martius Solms-laubach) meal diets supplemented with Maxigrain* Enzyme for growing pulllets. Journal of Raw Material Research Nigeria. 10(2): 18-44 Mahmood M, Sial AR, Saima, Akram M, Pasha TN & Jabbar MA. 2014. Effect of dietary energy levels on growth performance and feed cost analysis in Japanese quail. Pakistan Journal of Zoology. 45(5): 1357-1362 Mangisah I, Tristiarti, Murningsih W, Nasoetion MH, Jayanti ES & Astuti Y. 2006. Kecernaan nutrien eceng gondok yang difermentasi dengan Aspergillus niger pada ayam broiler. Journal of Indonesian Tropical Animal Agricultural. 31 (2): 124-128 Maulana IT, Sukraso & Damayanti S. 2014 .Kandungan asam lemak dalam minyak ikan Indonesia. Jurnal Ilmu dan Teknologi Kelautan Tropis. 6(1): 121-130 Metwally AA, El-Gellal AM & El-Sawaisi SM. 2009). Effect of silymarin on lipid metabolism in rat. World Applied Sciences Journal. 6 (12): 1634-1637 Mona MH, Morsy AS & Hasan AM. 2013. Egg yolk cholesterol and productive performance of laying hens influenced by dietary crude fiber levels under drinking natural salin water. Journal of Animal and Poultry Production. 4(3): 161-176 Muhammad M, Peter S, James G & Wosilat A. 2015. Growth performance of growing quails (Coturnix japonica) fed graded levels of Neem. International Journal of Applied Research. 1(2): 04-07 NRC.1994. Nutrient Requirement of Poultry. 9th Edition. Wahington D.C (US): National Academy Odo BI & Nnadi AE. 2014. Growth response of quails (Coturnix coturnix japonica) to varying levels of cassava (Manihot esculenta) tuber meal as a replacement for maize (Zea mays). American Journal of Experimental Agricultural. 4(12): 1898-1903 Riswandi. 2014. Kualitas silase eceng gondok (Eichhornia crassipes) dengan penambahan dedak halus dan ubi kayu. Jurnal Peternakan Sriwijaya. 3(1): 1-6 Rusmana,D. 2007. Pengaruh substitusi minyak sawit oleh minyak ikan lemuru dan suplementasi vitamin E dalam ransum ayam broiler terhadap performans. Jurnal Ilmu Ternak. 7(2): 101-106 Saha S. & Ray AK. 2011. Evaluation of nutritive value of water hyacinth (Eichhornia crassipes) leaf meal in compound diets for rohu Labeo rohita (Hamilton, 1822) fingerlings after fermentation with two bacterial strains isolated from fish gut. Turkish Journal of Fisheries and Aquatic Science. 11: 199-207 Sastrodihardjo S, Suci DM & Cahyanto MN. 1998. Penggunaan Minyak Ikan Lemuru dan Minyak Kelapa Sawit dalam ransum terhadap Kandungan Asam lemak Omega 3 dan Omega 6 dalam Kuning Telur Ayam. Bogor (ID): Seminar Nasional Peternakan dan Veteriner. Penelitian dan Pengembangan Pertanian Savory CJ & Gentle MJ. 1976. Changes in food intake and gut size in Japanese quail in response to manipulation of dietary fibre content. British Poultry Science. 17(6): 571-580 Sotolu AO & Sule SO. 2011. Digestibility and performance of water hyacinth meal in the diets of African catfish (Clarias gariepinus BURCHELL, 1822). Tropical and Subtropical Agroecosystem. 14: 245-250 Sim JS, Kitts WD & Bragg DB. 1984. Effect of dietary saponin on egg cholesterol level and laying hen performance. Canadian Journal of Animal Science. 64: 97-98 Tyagi T & Agarwal M. 2017. Antioxidant properties and phenolic compound in methanolic extracts of Eichornia crassipes. Reserarch journal of Phytochemistry. 11(2): 85-89. Tolik D, Polawska E, Charuta A, Nowaczewski S & Cooper R. 2014.Characteristics of egg parts, chemical composition and nutritive value of Japanese quail eggs-a review. Folia Biological (Krakow). 62 (4): 287-292 Tunsaringkarn T, Tungjaroenchai W & Siriwong W. 2013. Nutrient benefits of quail (Coturnix coturnix japonica) eggs. International Journal of Scientific and Research Publications. 3(5): 1-8

ABSTRACTThis study aimed to analyze the factors that influence customer decisions in using Islamic mobile banking services. In this study, a total of 200 respondents were collected through purposive sampling technique with the criteria of having used or currently using mobile banking services from Islamic banks in Semarang City, respondents answered online surveys through google forms as primary data collection. The methodology in this study was using PLS-SEM. The study findings show that the factors of mob mentality, reputation, perceived risk, and Islamic financial literacy have a positive and significant influence on the decision to use Islamic mobile banking. The four factors have a total influence of 87% on the decision to use Islamic mobile banking services. This finding implies that these factors need to be considered by customers and banks. Islamic banking must continue to strive for a level of security, data confidentiality and customer trust in a more creative, convenient, and effective mobile banking features and services system so that customers still feel their decision to use Islamic mobile banking services is right.Keywords: Mob Mentality, Reputation, Perceived Risk, Islamic Financial Literacy. ABSTRAKStudi ini memiliki tujuan untuk menganalisis faktor-faktor yang berpengaruh terhadap keputusan nasabah dalam menggunakan layanan mobile banking syariah. Pada studi ini, dikumpulkan sejumlah 200 responden melalui teknik purposive sampling dengan kriteria pernah atau sedang menggunakan layanan mobile banking dari bank syariah di Kota Semarang, responden menjawab survei secara online melalui google forms sebagai pengumpulan data primer. Metodologi pada penelitian ini yaitu menggunakan PLS-SEM. Hasilnya menunjukkan bahwa faktor-faktor mentalitas gerombolan, reputasi, persepsi akan resiko, dan literasi keuangan syariah memiliki pengaruh positif dan signifikan terhadap keputusan penggunaan mobile banking syariah. Keempat faktor tersebut memiliki total pengaruh sebesar 87% terhadap keputusan penggunaan layanan mobile banking syariah. Penemuan ini memberikan implikasi bahwa faktor-faktor tersebut perlu dipertimbangkan oleh nasabah dan pihak perbankan. Perbankan syariah harus tetap mengupayakan tingkat keamanan, kerahasiaan data dan kepercayaan nasabah dalam sistem fitur dan layanan mobile banking yang lebih kreatif, nyaman, serta efektif agar nasabah tetap merasa keputusannya menggunakan layanan mobile banking syariah adalah tepat.Kata Kunci: Mob Mentality, Reputation, Perceived Risk, Islamic Financial Literacy. REFFERENCES Alkhowaiter, W. A. (2020). Digital payment and banking adoption research in Gulf countries: A systematic literature review. International Journal of Information Management, 53. doi:10.1016/j.ijinfomgt.2020.102102 Ammari-Bahri, N., Coulibaly, D., & Ben Mimoun, M. S. (2020). The bandwagon luxury consumption in Tunisian case: The roles of independent and interdependent self concept. Journal of Retailing and Consumer Services, 52. doi:10.1016/j.jretconser.2019.101903 Bank Indonesia. (2021). Gaya hidup semakin digital, perbankan kurangi jumlah mesin ATM. Retrieved from blob:https://databoks.katadata.co.id/7d49cab2-a51c-4b92-a225-183a439aec4d Bank Indonesia. (2022). Pertumbuhan tahunan nilai transaksi uang elektronik dan perbankan digital. Retrieved from https://databoks.katadata.co.id/datapublish/2022/05/31/nilai-transaksi-uang-elektronik-dan-perbankan-digital-tumbuh-pesat-pada-april-2022 Butt, I., Ul-haq, S., Shareef, M. A., & Chowdhury, A. H. (2022). Ethical reputation and retail bank selection: a sequential exploratory mixed- methods study in an emerging economy. International Journal of Bank Marketing, 40 (7): 1526-1554. doi:10.1108/IJBM-03-2021-0104 CNBC Indonesia. (2021). Gegara ini, mobile banking Bank Syariah Indonesia melesat 98%. Retrieved from https://www.cnbcindonesia.com/syariah/20210823140844-29-270488/gegara-ini-mobile-banking-bank-syariah-indonesia-melesat-98/amp Dila, F. (2019). Hubungan antara bandwagon effect dan celebrity worship pada penggemar K-POP. Thesis Undergraduate Faculty of Psychology, Universitas Sumatra Utara. Elhajjar, S., & Ouaida, F. (2020). An analysis of factors affecting mobile banking adoption. International Journal of Bank Marketing, 38(2), 352–367. doi:10.1108/IJBM-02-2019-0055 Esthiningrum, A., & Sari, S. P. (2019). Pendekatan Theory Rasoned Action (TRA) dan Technology Acceptance Model (TAM) dalam minat transaksi menggunakan E-Money. Proceeding of Paradigma Pengembangan Ekonomi Kreatif di Era 4.0, 6(2), 163–172. Gbongli, K.., Peng, Y., & Ackah, O. (2016). Selection and ranking of perceived risk associated with mobile banking in West Africa. An AHP Approach from customers’ perspective. International Journal of Scientific & Engineering Research, 7(1), 80-86. Ghozali, I. (2014). Partial least squares, konsep, teknik, dan aplikasi menggunakan program SmartPLS 3.2.9 untuk peneliti. Semarang: Badan Penerbit Universitas Diponegoro. Ichwan, A., & Ghofur, R. A. (2020). Pengaruh Technology Acceptance Model terhadap keputusan muzakki membayar zakat melalui fintech Gopay. Jurnal Ilmiah Ekonomi Islam, 6(02), 129–135. doi:10.29040/jiei.v6i2.1011 Khan, L., & Arif, I. (2022). Islamic financial literacy and intention to use Islamic banking: A role of financial considerations. Journal of Finance & Economics Research, 7(1), 47–59. doi:10.20547/jfer2207104 Kurniasih, P. (2019). Faktor-faktor yang mempengaruhi keputusan konsumen dalm membeli sayuran organik di Kota Salatiga. Theses of Undergraduate Faculty of Agriculture and Business. Universitas Kristen Satya Wacana. Linda & Bloom, C. (2017). The bandwagon effect. Retrieved from https://www.psychologytoday.com/us/blog/stronger-the-broken-places/201708/the-bandwagon-effect?amp Muhammad, M., Sirat, A. H., & Hadady, E. H. (2023). The effect of Islamic financial literacy on the decision to use Islamic banking services in the City of Ternate with religion as a moderating variable. Jurnal Manajemen Bisnis, 10(1), 177–189. doi:10.33096/jmb.v10i1.489 Narteh, B., & Braimah, M. (2020). Corporate reputation and retail bank selection: the moderating role of brand image. International Journal of Retail and Distribution Management, 48(2), 109–127. doi:10.1108/IJRDM-08-2017-0164 Nguyen, Y. T. H., Tapanainen, T., & Nguyen, H. T. T. (2022). Reputation and its consequences in Fintech services: the case of mobile banking. International Journal of Bank Marketing, 40(7), 1364–1397. doi:10.1108/IJBM-08-2021-0371 Pala, F., Erdoğdu, A., Ali, M., Alnori, F., & Barut, A. (2023). Analyzing the linkage between Islamic financial literacy and Islamic banking services adoption: Evidence from Turkey. Journal of Islamic Accounting and Business Research. doi:10.1108/JIABR-12-2021-0324 Rahim, S. H. A., Rashid, R. A., & Hamed, A. B. (2016). Islamic financial literacy and its determinants among university students: An exploratory factor analysis. International Journal of Economics and Financial Issues, 6(7S), 32–35. Roemanasari, F., Sabela, J., & Rusgianto, S. (2022). Islamic financial literacy and financial behavior on investment intention. Jurnal Ilmu Ekonomi Terapan, 7(2), 239–250. doi:10.20473/jiet.v7i2.40679 Tan, E., & Lau, J. L. (2016). Behavioural intention to adopt mobile banking among the millennial generation. Young Consumers, 17(1), 18-315. doi:10.1108/YC-07-2015-00537 Thapa, S., Guzmán, F., & Paswan, A. K. (2022). How isolation leads to purchasing luxury brands: The moderating effects of COVID-19 anxiety and social capital. Journal of Product and Brand Management, 31(6), 984–1001. doi:10.1108/JPBM-05-2021-3500 Yudistira, A. (2022). Pengaruh bandwagon effect,veblen effect, dan pendapatan terhadap keputusan pembelian sepeda di masa pandemi Covid-19. Jurnal Ilmiah Mahasiswa FEB Universitas Brawijaya, 10(2), 1-17.

Follicular lymphoma (FL) is the most common type of indolent lymphoma in the Western world, accounting for approximately 30% of lymphoma cases. FL is known for its recurrent nature, necessitating diverse treatment options. The introduction of rituximab, an anti-CD20 antibody, has greatly improved FL outcomes and paved the way for targeted therapies. In this review, we thoroughly explore the structure, mechanism of action, clinical outcomes, and side effects of currently approved monoclonal antibodies (mAb) for FL. Furthermore, we provide insights into ongoing clinical trials and emerging monoclonal antibodies that hold promise for the future of FL treatment. A comprehensive literature search was conducted using various medical databases, including ASH and ASCO publications, as well as PubMed. The clinicaltrials.gov website was used to compile a list of investigational monoclonal antibodies from ongoing clinical trials. The future of antibody-based therapy for follicular lymphoma shows great promise, with a focus on enhancing antibody efficacy, prioritizing optimized combination therapies to address treatment resistance, and evaluating bispecific antibodies as first-line therapies, all while carefully balancing risks and benefits and sequencing treatments appropriately for better disease management. These directions have the potential to establish antibodies as a central component of follicular lymphoma treatment. Article Details How to Cite MOUSTAFA, Muhamad Alhaj. A Comprehensive Review of Monoclonal Antibodies for the Treatment of Follicular Lymphoma Including Both Approved and Investigational Options. Medical Research Archives, [S.l.], v. 11, n. 11, nov. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4745>. Date accessed: 02 dec. 2023. doi: https://doi.org/10.18103/mra.v11i11.4745. ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian Issue Vol 11 No 11 (2023): November Issue, Vol.11, Issue 11 Section Research Articles The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives. References 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569 2. Cerhan JR. Epidemiology of Follicular Lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631-646. doi:10.1016/j.hoc.2020.02.001 3. Kaseb H, Ali MA, Koshy NV. Follicular Lymphoma. In: StatPearls. StatPearls Publishing; 2023. Accessed April 8, 2023. http://www.ncbi.nlm.nih.gov/books/NBK538206/ 4. Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175-183. doi:10.1007/s00277-018-3501-8 5. Mozas P, Sorigué M, López-Guillermo A. Follicular lymphoma: an update on diagnosis, prognosis, and management. Med Clin (Barc). 2021;157(9):440-448. doi:10.1016/j.medcli.2021.03.041 6. Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma - treatment and prognostic factors. Rev Bras Hematol E Hemoter. 2012;34(1):54-59. doi:10.5581/1516-8484.20120015 7. Illidge T, Chan C. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma. 2008;49(7):1263-1273. doi:10.1080/10428190802090805 8. Steffanoni S, Ghielmini M, Moccia A. Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. Expert Rev Anticancer Ther. 2015;15(11):1337-1349. doi:10.1586/14737140.2015.1092386 9. Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematol Am Soc Hematol Educ Program. 2018;2018(1):194-199. doi:10.1182/asheducation-2018.1.194 10. Marofi F, Rahman HS, Achmad MH, et al. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Front Immunol. 2021;12:681984. doi:10.3389/fimmu.2021.681984 11. Bhatt VR, Armitage JO. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. Expert Opin Biol Ther. 2016;16(1):57-66. doi:10.1517/14712598.2016.1096341 12. Lin Z, Liu L, Li Z, Xu B. Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting. Exp Hematol Oncol. 2023;12(1):41. doi:10.1186/s40164-023-00404-3 13. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045. doi:10.1182/blood-2010-03-276246 14. van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol. 2011;24(2):231-256. doi:10.1016/j.beha.2011.03.002 15. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598 16. Johnston PB, Bondly C, Micallef INM. Ibritumomab tiuxetan for non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther. 2006;6(6):861-869. doi:10.1586/14737140.6.6.861 17. Gondran C, Ysebaert L. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma]. Bull Cancer (Paris). 2022;109(11):1105-1106. doi:10.1016/j.bulcan.2022.07.010 18. Allen HC, Sharma P. Histology, Plasma Cells. In: StatPearls. StatPearls Publishing; 2023. Accessed April 11, 2023. http://www.ncbi.nlm.nih.gov/books/NBK556082/ 19. Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Monoclonal antibodies. Mol Pathol MP. 2000;53(3):111-117. doi:10.1136/mp.53.3.111 20. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-497. doi:10.1038/256495a0 21. Dunn DL. Monoclonal antibodies for diagnosis and treatment. Arch Surg Chic Ill 1960. 1993;128(11):1274-1280. doi:10.1001/archsurg.1993.01420230102016 22. Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal Antibodies: Past, Present and Future. Handb Exp Pharmacol. 2019;260:81-141. doi:10.1007/164_2019_323 23. Di Pauli F, Berger T, Reindl M. Monoclonal antibodies in the treatment of multiple sclerosis. Curr Med Chem. 2009;16(36):4858-4868. doi:10.2174/092986709789909585 24. Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325(10):1015. doi:10.1001/jama.2021.1225 25. Kaur N, Goyal A, Sindhu RK. Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anticancer Agents Med Chem. 2020;20(16):1895-1907. doi:10.2174/1871520620666200703191653 26. Yamada T. Therapeutic monoclonal antibodies. Keio J Med. 2011;60(2):37-46. doi:10.2302/kjm.60.37 27. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. 28. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab: Anticancer Drugs. 2002;13:S3-S10. doi:10.1097/00001813-200211002-00002 29. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61(13):5137-5144. 30. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-3908. 31. Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638-1651. doi:10.1002/ajh.26737 32. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(15):1986-1992. doi:10.1200/JCO.2006.06.4618 33. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732. doi:10.1182/blood-2005-01-0016 34. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. doi:10.1182/blood-2004-08-3175 35. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(28):4579-4586. doi:10.1200/JCO.2007.13.5376 36. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824-4831. doi:10.1182/blood-2008-04-153189 37. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101-106. doi:10.1182/blood.v97.1.101 38. Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-4423. doi:10.1182/blood-2003-10-3411 39. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(6):1103-1108. doi:10.1200/JCO.2005.12.052 40. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet Lond Engl. 2011;377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7 41. Martinelli G, Schmitz SFH, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(29):4480-4484. doi:10.1200/JCO.2010.28.4786 42. Hanif N, Anwer F. Rituximab. In: StatPearls. StatPearls Publishing; 2023. Accessed April 15, 2023. http://www.ncbi.nlm.nih.gov/books/NBK564374/ 43. Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29-45. doi:10.1111/bjh.15232 44. Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin’s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015;38(4):185-192. doi:10.1159/000381524 45. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402. doi:10.1182/blood-2009-06-225979 46. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358-367. doi:10.1182/blood-2010-09-305847 47. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol OncolJ Hematol Oncol. 2014;7:58. doi:10.1186/s13045-014-0058-4 48. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137-1143. doi:10.1182/blood-2013-01-481341 49. Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R. Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol. 2021;39(2):215-221. doi:10.1002/hon.2828 50. Riley MB. Ibritumomab tiuxetan. Clin J Oncol Nurs. 2003;7(1):110-112. doi:10.1188/03.CJON.109-112 51. Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(16):1977-1983. doi:10.1200/JCO.2012.45.6400 52. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(15):3262-3269. doi:10.1200/JCO.2002.11.017 53. Rieger K, De Filippi R, Lindén O, et al. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. Ann Hematol. 2022;101(4):781-788. doi:10.1007/s00277-022-04781-3 54. Alhaj Moustafa M, Borah BJ, Moriarty JP, et al. Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas. Clin Lymphoma Myeloma Leuk. 2023;23(4):259-265. doi:10.1016/j.clml.2023.01.010 55. Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med. 2021;11(5):355. doi:10.3390/jpm11050355 56. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065. doi:10.1016/S1470-2045(22)00335-7 57. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X 58. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9 59. Grigor EJM, Fergusson D, Kekre N, et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019;33(2):98-110. doi:10.1016/j.tmrv.2019.01.005 60. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol. 2005;17(3):290-297. doi:10.1016/j.coi.2005.03.005 61. Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021;219:107709. doi:10.1016/j.pharmthera.2020.107709 62. Dakappagari N, Ho SN, Gascoyne RD, Ranuio J, Weng AP, Tangri S. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry B Clin Cytom. 2012;82(2):112-119. doi:10.1002/cyto.b.20631 63. Deeks ED. Polatuzumab Vedotin: First Global Approval. Drugs. 2019;79(13):1467-1475. doi:10.1007/s40265-019-01175-0 64. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-742. 65. Rosenbaum CA, Jung SH, Pitcher B, et al. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol. 2019;185(1):53-64. doi:10.1111/bjh.15768 66. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-5495. doi:10.1182/blood-2007-10-117671 67. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698-3704. doi:10.1182/blood-2011-09-378323 68. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(20):3346-3353. doi:10.1200/JCO.2008.19.9117 69. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(9):1870-1876. doi:10.1093/annonc/mdq027 70. Tobinai K, Ogura M, Kobayashi Y, et al. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci. 2011;102(2):432-438. doi:10.1111/j.1349-7006.2010.01809.x 71. Ganjoo KN, de Vos S, Pohlman BL, et al. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. Leuk Lymphoma. 2015;56(1):42-48. doi:10.3109/10428194.2014.911859 72. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(16):3051-3059. doi:10.1200/JCO.2003.01.082 73. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(12):2085-2093. doi:10.1200/JCO.2009.25.1900 74. Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840-1845. doi:10.1111/j.1349-7006.2010.01601.x 75. Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456. doi:10.1038/s41409-017-0019-y 76. Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634-2645. doi:10.1182/blood.2020007512 77. Salles G, Gopal AK, Minnema MC, et al. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(5):275-284. doi:10.1016/j.clml.2018.12.013 78. Fanale M, Assouline S, Kuruvilla J, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol. 2014;164(2):258-265. doi:10.1111/bjh.12630 79. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(19):4390-4398. doi:10.1200/JCO.2005.09.018 80. Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137(5):637-645. doi:10.1182/blood.2019004753 81. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(25):4143-4149. doi:10.1200/JCO.2006.05.8198 82. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(24):5696-5704. doi:10.1200/JCO.2005.14.803 83. Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(3):314-320. doi:10.1200/JCO.2012.42.4101 84. Nastoupil LJ, Chin CK, Westin JR, et al. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(4):1143-1151. doi:10.1182/bloodadvances.2021006240 85. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008;113(10):2714-2723. doi:10.1002/cncr.23890 86. Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013;119(21):3797-3804. doi:10.1002/cncr.28299 87. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254-e265. doi:10.1016/S2352-3026(19)30026-2 88. Diefenbach C, Kahl BS, McMillan A, et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol. 2021;8(12):e891-e901. doi:10.1016/S2352-3026(21)00311-2 89. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet Lond Engl. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8 90. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327-e339. doi:10.1016/S2352-3026(22)00072-2 91. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(18):1959-1970. doi:10.1200/JCO.20.03175 92. Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021;5(2):607-612. doi:10.1182/bloodadvances.2020001792 93. Tapia-Galisteo A, Compte M, Álvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics. 2023;13(3):1028-1041. doi:10.7150/thno.81494 94. Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2020;1(1):86-98. doi:10.1038/s43018-019-0004-z 95. Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. Immunology. 2023;169(4):389-399. doi:10.1111/imm.13636 96. Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(5):573-583. doi:10.1200/JCO.2012.42.7211 97. Kolstad A, Illidge T, Bolstad N, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091-4101. doi:10.1182/bloodadvances.2020002583 98. Palomba ML, Till BG, Park SI, et al. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. Clin Lymphoma Myeloma Leuk. 2022;22(7):e443-e451. doi:10.1016/j.clml.2021.12.010 99. Morschhauser F, Ghosh N, Lossos IS, et al. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood Cancer J. 2021;11(8):147. doi:10.1038/s41408-021-00539-8 100. Czuczman MS, Hess G, Gadeberg OV, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157(4):438-445. doi:10.1111/j.1365-2141.2012.09086.x 101. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69-77. doi:10.1016/S1470-2045(13)70551-5 102. Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(9):2356-2362. doi:10.1093/annonc/mdr620